Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FABULOUS study of treatment-free interval versus continuous Dara-Rd in newly diagnosed multiple myeloma
NL-OMON59383Phase 3Recruiting
- Sponsor
- HOVON
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoints: Event-free survival and Progression-free survival. Started May 2024; status: recruiting.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59383.